Evidence map›Paper›PMID 27313992›Full record

ArticleFrontiers in cellular and infection microbiology2016

Toxoplasma gondii-Derived Synthetic Peptides Containing B- and T-Cell Epitopes from GRA2 Protein Are Able to Enhance Mice Survival in a Model of Experimental Toxoplasmosis.

Luciana M Bastos, Arlindo G Macêdo, Murilo V Silva, Fernanda M Santiago, Eliezer L P Ramos, Fabiana A A Santos, Carlos P Pirovani, Luiz R Goulart, Tiago W P Mineo, José R Mineo

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
4.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Pharmaceutics · 2021
    Article
  6. Advances inVaccines · 2021
    Review
  7. Article
  8. Vaccines · 2020
    Article
  9. Article
  10. Epitope-based vaccine as a universal vaccination strategy againstJournal of advanced veterinary and animal research · 2019
    Review
  11. Article
  12. Article
  13. Protective Efficacy Against Acute and ChronicFrontiers in microbiology · 2018
    Article
  14. Article
  15. Immunization withFrontiers in immunology · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Luciana M BastosLaboratório de Imunoparasitologia "Dr. Mário Endsfeldz Camargo", Instituto de Ciências Biomédicas, Universidade Federal de UberlândiaUberlândia, Brazil; Laboratório de Nanobiotecnologia, Instituto de Genética e Bioquímica, Universidade Federal de UberlândiaUberlândia, Brazil.
Arlindo G MacêdoLaboratório de Imunoparasitologia "Dr. Mário Endsfeldz Camargo", Instituto de Ciências Biomédicas, Universidade Federal de Uberlândia Uberlândia, Brazil.
Murilo V SilvaLaboratório de Imunoparasitologia "Dr. Mário Endsfeldz Camargo", Instituto de Ciências Biomédicas, Universidade Federal de Uberlândia Uberlândia, Brazil.
Fernanda M SantiagoLaboratório de Imunoparasitologia "Dr. Mário Endsfeldz Camargo", Instituto de Ciências Biomédicas, Universidade Federal de Uberlândia Uberlândia, Brazil.
Eliezer L P RamosLaboratório de Imunoparasitologia "Dr. Mário Endsfeldz Camargo", Instituto de Ciências Biomédicas, Universidade Federal de Uberlândia Uberlândia, Brazil.
Fabiana A A SantosLaboratório de Nanobiotecnologia, Instituto de Genética e Bioquímica, Universidade Federal de Uberlândia Uberlândia, Brazil.
Carlos P PirovaniCentro de Biotecnologia e Genética, Universidade Estadual de Santa Cruz Ilhéus, Brazil.
Luiz R GoulartLaboratório de Nanobiotecnologia, Instituto de Genética e Bioquímica, Universidade Federal de Uberlândia Uberlândia, Brazil.
Tiago W P MineoLaboratório de Imunoparasitologia "Dr. Mário Endsfeldz Camargo", Instituto de Ciências Biomédicas, Universidade Federal de Uberlândia Uberlândia, Brazil.
José R MineoLaboratório de Imunoparasitologia "Dr. Mário Endsfeldz Camargo", Instituto de Ciências Biomédicas, Universidade Federal de Uberlândia Uberlândia, Brazil.
Universidade Federal de Uberlândia · BRUniversidade Estadual de Santa Cruz · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Toxoplasmosis is a zoonosis distributed all over the world, which the etiologic agent is an intracellular protozoan parasite, Toxoplasma gondii. This disease may cause abortions and severe diseases in many warm-blood hosts, including humans, particularly the immunocompromised patients. The parasite specialized secretory organelles, as micronemes, rhoptries and dense granules, are critical for the successful parasitism. The dense granule protein 2 (GRA2) is a parasite immunogenic protein secreted during infections and previous studies have been shown that this parasite component is crucial for the formation of intravacuolar membranous nanotubular network (MNN), as well as for secretion into the vacuole and spatial organization of the parasites within the vacuole. In the present study, we produced a monoclonal antibody to GRA2 (C3C5 mAb, isotype IgG2b), mapped the immunodominant epitope of the protein by phage display and built GRA2 synthetic epitopes to evaluate their ability to protect mice in a model of experimental infection. Our results showed that synthetic peptides for B- and T-cell epitopes are able to improve survival of immunized animals. In contrast with non-immunized animals, the immunized mice with both B- and T-cell epitopes had a better balance of cytokines and demonstrated higher levels of IL-10, IL-4 and IL-17 production, though similar levels of TNF-α and IL-6 were observed. The immunization with both B- and T-cell epitopes resulted in survival rate higher than 85% of the challenged mice. Overall, these results demonstrate that immunization with synthetic epitopes for both B- and T-cells from GRA2 protein can be more effective to protect against infection by T. gondii.

Indexed as

Adjuvants, ImmunologicAmino Acid SequenceAnimalsAntibodies, MonoclonalAntibodies, ProtozoanAntigens, ProtozoanCytokinesDisease Models, AnimalEpitopes, B-LymphocyteEpitopes, T-LymphocyteFemaleFluorescent Antibody Technique, IndirectImmunity, HumoralInterleukinsMiceMice, Inbred C57BLAdjuvants, ImmunologicAntibodies, MonoclonalAntibodies, ProtozoanAntigens, ProtozoanCytokinesEpitopes, B-LymphocyteEpitopes, T-LymphocyteGra2 protein, Toxoplasma gondiiInterleukinsPeptidesProtozoan ProteinsProtozoan Vaccinessoluble tachyzoite antigen, Toxoplasma gondiiB- and T-cell epitopesGRA2monoclonal antibodyToxoplasma gondii

Identifiers

PMID27313992
PMCPMC4888622
OpenAlexW2418797430

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.